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ABSTRACT

OBJECTIVE: The objective of this selective EBM review is to determine whether or not
botulinum toxin injections improve the freezing of gait (FOG) episodes experienced by patients
diagnosed with Parkinson’s disease (PD).
STUDY DESIGN: This review is based on three randomized controlled trials published in 2004,
2005, and 2007. All of the studies compared the efficacy as well as safety of using botulin toxin
injections to treat FOG episodes experienced by PD patients.
DATA SOURCES: All articles used were published in English, in peer-reviewed journals, and
were found using PubMed searches.
OUTCOMES MEASURED: For all studies, the safety and efficacy of botulin toxin injections
in the legs of patients with PD who experience FOG episodes was evaluated using clinical
assessment as well as questionnaires such as the United Parkinson’s Disease Rating Scale
(UPDRS). The post-treatment measurements were compared to pre-treatment baseline
assessments to determine any improvements.
RESULTS: Leg weakness, skin changes, and increase in number of falls were a few adverse
reactions that occurred after treatment with botulinum toxin injections. The three studies
completed by Wieler, Fernandez, and Gurevich had statistically insignificant results.
CONCLUSION: All three of the RCTs that were evaluated did not demonstrate a statistically
significant difference after the patients received botulinum toxin injections. Botulinum toxin
injections are not proven to be effective in the treatment of PD FOG episodes. However, as there
were no life threatening or extremely unsafe adverse reactions, further future studies would be
warranted in which a larger sample size could be evaluated.
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INTRODUCTION
Parkinson’s disease (PD) is a degenerative, chronic and progressive disease that
specifically targets and affects the dopaminergic cells of the substantia nigra causing cognitive
and movement disorders.1 The disease is fairly variable from patient to patient.1 Cognitive
impairments range from dementia to mood and sleep dysfunctions to psychosis.1 Although
cognitive dysfunction can be debilitating, this paper focuses on the physical movement disorders
experienced by PD patients, including bradykinesia, balance disorders, rigidity, tremors, and
freezing of gait (FOG) episodes.2 It is important to note that PD is not a fatal disease in and of
itself, but morbidity is related to PD-related complications including falls, pneumonia, or
choking.1
Parkinson’s disease is the second most common neurodegenerative disease generally
diagnosed in patients around 60 years old.3 It is a growing disease in the United States as the
population continues to age.4 Currently, PD affects 1 million patients in the United States and
about 7 to 10 million people worldwide.4 It is projected that this number will nearly double by
the year 2030.4 An estimated 60,000 Americans are diagnosed each year.4
The economic burden associated with PD is expected to increase as the number of
patients diagnosed with this disease continues to climb.3 In the year 2010, it was estimated that
the direct costs of PD was around $14.4 billion.3 Medication costs alone for a single individual
battling PD averages to about $2,500 a year and therapeutic surgery is approximately $100,000
per patient.3 When indirect costs associated with PD, such as lost income due to illness and
social security payments are added to the direct costs, it is projected that $25 billion per year is
spent just in the United States alone.3 Although an exact number of health care visits per year due
to PD is unknown, patients with PD experience worsening symptoms as their disease progresses,
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leading to higher direct costs due to an increase in medications, hospitalizations, office visits,
and need for nursing home care.3 Fifteen percent of PD patients are found in nursing homes,
which accounts for about 60% of the direct costs accumulated.3
The exact cause of PD is unknown, however, it is thought to be a combination of family
history, genetics, and environmental causes. One of the most important risk factors associated
with PD is aging.2 Fifteen percent of patients diagnosed with PD have a family member with PD
as well.2 It has been found that when PD occurs at an early age it is often associated with a gene
mutation such as parkin, PINK1, LRRK2, DJ-1, and glucocerebrosidase.2
As stated earlier, the presentation and disease progression can vary greatly from patient to
patient. The most common presenting symptom is an intermittent resting tremor.2 Parkinson’s
disease classically presents with one-sided symptoms that begin to progress over the years and
spread to include symptoms affecting the other side of the body as well.2 PD may be detected by
the decreased ability to perform repetitive movements.2 Another key feature, bradykinesia, is the
reason for the stooped, shuffled gait characteristic of a PD patient.2 Rigidity is commonly seen in
PD which causes stiffness and decreased flexibility. Secondary to these motor dysfunctions,
patients may experience freezing of gait (FOG). Patients describe FOG as feeling as if their feet
are glued to the floor.2 This sensation is most commonly experienced when patients attempt to
take a first step while walking.2 This sensation greatly increases a patient’s risk for falling.2
Other key features of the disease are micrographia, mask-like expressions, unwanted
accelerations of speech and gait, loss of smell, mood disorder, memory difficulties, and
orthostatic hypotension.2
Parkinson’s disease is generally treated symptomatically, as there is no cure. The hope is
that by controlling the symptoms, disease progression can be slowed and complications due to
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PD can be prevented. The decision to begin treatment is generally made when the symptoms are
negatively affecting ability to perform activities of daily living and quality of life.2
There are six classes of drugs used to treat PD. The most effective and commonly used
medication is Levodopa, which is usually given as a combination pill of Carbidopa and
Levodopa called Sinemet.2 The biggest concern with Levodopa is that over time, motorfluctuations begin to occur including “wearing off” effect. The “wearing off” effect is when the
medication begins to wear off before the next scheduled dose.2 Monoamine oxidase inhibitors
are another group of medications for PD that work to inactivate the breakdown of dopamine.2
These work to decrease the symptoms of PD by allowing dopamine to remain in the brain for a
longer period of time.2 Other medications include dopamine agonists, Catechol-O-methyl
transferase (COMT) inhibitors, and Amantadine.2 Management of common conditions found in
PD patients such as depression, sleep disorders, dementia, psychosis and hallucinations are all
treated separately and individualized to each patient.2
Currently, there is not a cure for PD and all the above treatments are aimed toward
slowing down the disease progression, improving symptoms, and preserving the ability to
perform activities of daily living.2 The method of treatment being proposed is whether or not
BTX being injected into the leg muscles of patients with PD may be used to further control the
number and severity of the FOG episodes in hopes that patients would experience less falls, less
injury, and retain more independence. The use of botulinum toxin (BTX), a gram-positive
anaerobe, is currently not a suggested or utilized treatment for PD.5
OBJECTIVE
The objective of this selective evidence based medicine review is to determine whether or
not BTX injections improve the episodes of FOG in PD patients.
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METHODS
Three studies were assessed: a double blind randomized, placebo-controlled pilot study5,
a two period cross over design RCT7, and a double blind randomized, placebo controlled,
parallel-group study8. The intervention being used in all three RCTs was BTX injections into the
gastrocnemius and soleus muscles of the leg while the comparison group received placebo
injections of saline into the gastrocnemius and soleus muscle complex. The studies selected were
determining whether or not there was a decrease in the FOG episodes experienced by PD
patients after BTX injections.
Data was collected using a detailed search of Cochrane Systematic review as well as
PubMed from the years 2004 to present. “Parkinson’s disease,” “freezing of gait,” and
“botulinum toxin injections” were keywords that were used in this search. Articles were selected
based on their relevance to clinical practice and importance to patient-oriented outcomes. All
articles chosen for this review were peer-reviewed and published in well-known journals.
Inclusion criteria for all three RCTs selected for review consisted of RCTs that were peer
reviewed and published within the past fifteen years. The studies needed to include PD patients
with FOG as a major complaint, that were severe enough to need treatment. Similarly, studies
were excluded if they not published in the past 15 years. Studies were also omitted if they did not
use UPDRS to measure outcomes.
The three RCTs selected, all reported statistics using mean change from baseline as well
as p-values. In the Wieler et al. study, independent T-Tests were used to examine differences
between groups and assess for carryover.6 Paired T-tests were performed to look for pooled
group effects without regard to order of treatment.6 In the Fernandez et al. study, all analyses
were performed using the SAS statistical software.7 Finally, in the Gurevich et al. study, they
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used mixed effects models for repeated measures to investigate changes over time in the
subject’s motor status to handle an unbalanced design where subjects have different number of
repeated measures.8
Table 1 : Demographics and Characteristics of included studies
Study

Type

Wieler
(2005)6

RCTDouble
blind
crossover
design

Fernan
dez
(2004)7

Gurevi
ch
(2007)8

#
Pati
ents
12

Age (yrs)

Inclusion criteria

Exclusion
Criteria

W/
D

Mean age
of 77
years

-Diagnosis of PD with FOG as a
major complaint
-Good locomotion between freezing
episodes
-Optimal, stable medical treatment
for PD
-Ability to keep accurate diaries and
attend scheduled visits

If unable
to keep a
daily diary

0

200-300 U of BTXA injections into
the medial and
lateral heads of the
gastrocnemius and
soleus for a total of
six injections.

-Presence of 3-4 cardinal features of
resting tremor, rigidity,
bradykinesia, and postural
instability, with a significant
sustained response to anti-PD
therapy
-A Hoehn and Yahr stage of 3
-Stable PD medication for at least
30 days
-FOG severe enough to need
treatment
-Optimized on their present anti-PD
therapy

None

0

BTX- type B 5,000
U or placebo was
injected into 4
areas of the soleusgastrocnemius
complex of the
predominantly
affected leg.

-PD patients during the “off” state
for at least 3 months.
-Diagnosed by 2 independent
movement disorders specialist
-Disabling FOG
-Scored at least a 14 in the FOG
questionnaire
-FOG episodes with duration of 3
seconds and more every day
affecting their ability to walk and
their ADLs.

-If unable
to walk
independe
ntly
-If had
been
exposed to
BTX-A in
the past.

0

BTX 150 IU was
injected into both
legs (50 IU into
medial and lateral
heads of the
gastrocnemius and
50 IU into the
soleus of each leg
for a total of 300
IU per patient).

(range 53
-79 years)

RCTDouble
Blind,
Placebo
Paralleldesign

14

RCTDouble
blind
placebodesign

11

Mean age
of 74
years
(range 61–
87 years)

Mean age
was 69.4
(Range 56
– 86
years)

Interventions

OUTCOMES MEASURED
All outcomes measured for this study were patient oriented outcomes (POEMs) related to
the safety and efficacy of the use BTX injections for FOG episodes experienced by PD patients.
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These outcomes were measured using United Parkinson’s Disease Rating Scale (UPDRS). The
UPDRS uses patient questionnaire as well as clinical observation to assess the activities of daily
living and motor abilities of PD patients.
RESULTS:
Three studies investigated the impact that BTX injections had on the FOG episodes
experienced by patients who had been diagnosed with PD. All three studies were RCTs: the first
study was a double blind, two-period cross over design,6 the second study was a double blind,
placebo parallel design,7 and the third study was a double-blind placebo design.8
In Wieler et al., twelve participants were selected, three women and nine men. The
sample of patients consisted of 53 to 79 year olds with PD, with the average patient being 77
years old.6 Patients were selected based on adherence to inclusion and exclusion criteria listed in
Table 1. The patients were randomly assigned to either a placebo saline injection group followed
by a BTX injection group, or a BTX injection group followed by a placebo saline injection
group.6 All participants were assessed at baseline and then received the first set of injections 4
weeks later.6 At week 8, patients were evaluated for any changes in their condition. At week 16,
the groups were switched and the next set of injections were given. At week 20, patients were
again assessed for any changes from baseline. The BTX group received 200-300 units, which
were injected into the medial and lateral heads of the gastrocnemius and into the soleus muscles
for a total of 16.25-25 U/injection into six different injection sites.6 At the follow up visits,
diaries, freezing of gait questionnaires, and UPDRS were used to assess basic mobility.6 A
Parkinson’s disease questionnaire (PDQ39 mobility) was used to assess quality of life.6
This study demonstrates that after BTX injections, there were no statistically significant
differences from the baseline visit to the post-treatment visit that were captured by the FOG-Q
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(p>0.18), UPDRS 14 (p>1.0), UPDRS 15 (p>1.0), PDQ39 mobility (p>0.95).6 The mean change
from baseline was 0, representing absolutely no changes post-treatment. Table 2 is an
independent T-test, which demonstrates the differences between the placebo and BTX groups.
There were no evidence of adverse effects, however one subject did report leg weakness
that lasted for one week post BTX injection that was described as “my legs felt like jelly for a
couple of days.”6 While there was no evidence of improvement, participant’s comments alluded
to possible improvements after injections.6 Another patient stated there was a decrease in
nocturnal leg cramping after BTX injections for approximately 3 weeks.6
Table 2: Mean difference at placebo baseline, placebo week 4, BTX baseline, and BTX week 4.6
Mean difference (SD)

P value

UPDRS 14

0 (SD= 0.26)

1.00

UPDRS 15

0 (SD=0.55)

1.00

In the Fernandez et al. study, fourteen participants were selected.7 The patient’s ages
ranged from 61 to 87 years old, with the mean age being 74.7 Participants had an average
duration of PD for ten years.7 Patients were selected based on having idiopathic PD and FOG
refractory to medical treatment as well as if they met inclusion criteria listed in Table 1.7 Of the
fourteen participants, nine were randomly selected to receive intramuscular BTX injections and
five were chosen to receive placebo.7 This group received 5000 U of BTX-B injections into four
areas of the soleus and gastrocnemius muscle of the predominantly affected leg.7 If both legs
seemed to be affected equally, then the side on which the disease process began was selected.7
This study did not show any statistically significant changes between the placebo and treatment
group at baseline and at 1 month post treatment (p>0.15).7 There was also no statistically
significant changes before and after treatment within the group of patients receiving BTX
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injections based on the UPDRS (p>0.80).7 The mean change from baseline was -0.6, which
proves that this intervention did not have an impact on the patients.7 Table 3 illustrates the scores
between the BTX and control groups.
The BTX injections were tolerated well by all patients in this study. The only adverse
effects that were reported were dry mouth, experienced by two patients, and festination, which is
an involuntary quickening of gait, reported by one patient.7
Table 3: UPDRS mean scores at baseline, and one month.7
UPDRS Score

Baseline score

1 month

BTX group
Control group

18.7
17.8

18.1
17.4

P value (1
month)
0.8
0.8

In the Gurevich et al. study, eleven participants were selected, three females and eight
males.8 The patient’s ages ranged from 56 to 86 years old with the mean age being 69.4 years
old.8 Patients were selected based on the inclusion and exclusion criteria listed in Table 1. Six
patients were randomly selected to receive BTX injections and five patients were assigned to
receive saline injections.8 Baseline assessments were done at four and two weeks before as well
as on the day of injection.8 The participants received 150 IU of BTX injections, 50 IU into the
medial and lateral heads of the gastrocnemius as well as 50 IU into the soleus, of each leg for a
total of 300 IU of BTX per participant.8 Post-injection, patients were evaluated at 2, 4, 8, 12, 16,
and 20 weeks during which activities of daily living were assessed using UDPRS.8
There were insignificant changes found from baseline based on the UPDRS motor scale
(p<0.10).8 Mean change from baseline was measured to be +2.0, which is small given the type
and size of the population.8 Table 4 demonstrates the changes between the placebo and BTX
groups.

Poole 9
Parkinson’s and BTX Injections
People participating in this study experienced numerous adverse effects. Of the six
patients receiving BTX injections, three patients reported leg weakness, as did two patients who
were receiving the placebo, however the leg weakness was not demonstrated by the clinical
assessment.8 Participants in both treatment and placebo group in the two to four weeks post
injection reported pain.8 One patient receiving BTX injections was diagnosed with xerotic
dermatitis in the six weeks following injection that lasted throughout the rest of the study.8
Another adverse affect was an increase in number of reported falls. This seemed to improve by
the end of the 20th week study, but overall, falls did increase significantly in the BTX group.8
Table 4: UPDRS mean change at baseline, 4 weeks, and 20 weeks.8
UPDRS motor
BTX injections
Control group

Baseline
33.0 (+10.7)
35.6 (+11.8)

4 weeks
38.2 (+15.2)
34.0 (+14.7)

20 weeks
43.8 (+8.3)
32.0 (+8.0)

P value
P<0.10
Insignificant

DISCUSSION:
Parkinson’s disease is an extremely debilitating disease with no imminent cure. Freezing
of gait is a common complaint that leads to an increase in number of falls leading to a greater
number of injuries and hospitalizations.4 While treatments are available that can treat symptoms
of PD as well as slow the progression, nothing has proven to completely treat and resolve the
associated problems of PD.2 BTX injections did not prove to be a promising addition to the
treatment options for PD.
The three RCT’s evaluated by this systematic review showed that the use of BTX
injections for the FOG experienced by PD patients does not prove to be affective in improving
motor abilities or activities of daily living.
BTX acts by binding to sites on cholinergic pre-synaptic nerve terminals and decreases
the release of acetylcholine.5 In doing this, it acts as a neuromuscular blocker.5 Therefore, BTX,
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while most popular for it’s cosmetic usages, can be therapeutic for a wide variety of conditions
including dystonias, spasticity, strabismus, and chronic pain issues.5 However, when BTX is
used in the wrong dose, dilution, or having been improperly stored, has been shown to have
adverse effects.5 Adverse reaction to BTX is more likely to be seen when being used as a therapy
rather than for cosmetic usage.5 A few commonly reported side effects include respiratory
problems, dysphagia, seizures, flulike syndrome, weakness, ptosis, or reaction at site of
injection.5
There are a few limitations in the RCTs used. Each study was quite small, which may
have precluded any ability to detect a significant benefit. A larger group may reveal benefits of
BTX injections that was unable to be seen here. Also, there is no known dose of BTX that has
been shown to be effective. Because of this, it is unknown if higher doses would have
contributed to more significant symptom reduction. Muscle selection is another limitation of
these studies as only the gastrocnemius-soleus complex was injected. In the future, other muscle
targets could be evaluated, for example, the muscles in the anterior compartment of the leg.
CONCLUSION:
BTX is used to treat a wide variety of disease and neurological symptoms ranging from
focal dystonias of the face or limbs to migraine headaches. Its use in the treatment of PD is still
nebulous. None of the studies evaluated in this review demonstrated a significant benefit of BTX
on the FOG episodes experienced by PD patients. Since no extreme adverse drug reactions were
shown to be an issue with this treatment, it may be beneficial to proceed with more studies in
order to further evaluate it’s safety and efficacy. Future studies should include a larger number of
subjects. The reviewed studies do not show extreme promise in any major developments in the
treatment for PD.
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